Engineering a pH-sensitive humanized infliximab with improved potency and developability using STEM™
Background: Tumor necrosis factor- inhibitors such as infliximab and adalimumab have transformed autoimmune disease treatment; however, infliximab is a mouse-human chimeric antibody that remains immunogenic, is associated with self-association/aggregation liability, and requires prolonged intravenous administration. We humanized infliximab and engineered infliximab-derived candidates with…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.